Hemostemix Inc.

DB:2VF0 Stock Report

Market Cap: €8.0m

Hemostemix Management

Management criteria checks 2/4

Hemostemix's CEO is Thomas Smeenk, appointed in Dec 2019, has a tenure of 5.08 years. directly owns 2.14% of the company’s shares, worth €170.60K. The average tenure of the management team and the board of directors is 4 years and 4.8 years respectively.

Key information

Thomas Smeenk

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5yrs
CEO ownership2.1%
Management average tenure4yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Thomas Smeenk's remuneration changed compared to Hemostemix's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$2m

Jun 30 2024n/an/a

-CA$2m

Mar 31 2024n/an/a

-CA$2m

Dec 31 2023n/an/a

-CA$3m

Sep 30 2023n/an/a

-CA$3m

Jun 30 2023n/an/a

-CA$4m

Mar 31 2023n/an/a

-CA$5m

Dec 31 2022CA$308kCA$208k

-CA$5m

Sep 30 2022n/an/a

-CA$7m

Jun 30 2022n/an/a

-CA$7m

Mar 31 2022n/an/a

-CA$7m

Dec 31 2021CA$224kCA$224k

-CA$6m

Sep 30 2021n/an/a

-CA$7m

Jun 30 2021n/an/a

-CA$8m

Mar 31 2021n/an/a

-CA$8m

Dec 31 2020CA$277kCA$277k

-CA$8m

Compensation vs Market: Insufficient data to establish whether Thomas's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.

CEO

Thomas Smeenk (62 yo)

5yrs

Tenure

CA$308,000

Compensation

Mr. Thomas A. Smeenk, BA, is the Co-founder of Hemostemix Inc. and serves as its President and Director since December 9, 2019 and November 26, 2019 respectively. He serves as the Chief Executive Officer o...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Smeenk
Co-Founder5yrsCA$308.00k2.14%
€ 170.6k
Christina Wu
Interim Chief Financial Officer4.8yrsCA$65.38kno data
Peter Pavlin
Vice President of Operations2.9yrsno datano data
Fraser Henderson
Chief Medical Officer3.2yrsno datano data

4.0yrs

Average Tenure

Experienced Management: 2VF0's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Thomas Smeenk
Co-Founder5.1yrsCA$308.00k2.14%
€ 170.6k
Peter Lacey
Independent Chairman4.8yrsno data4.33%
€ 345.6k
Norman C. Wong
Member of Scientific Advisory Board7yrsno datano data
Alan Lumsden
Member of Scientific Advisory Boardno datano datano data
David Tsubouchi
Member of Board of Advisors4.7yrsno datano data
Loran Swanberg
Independent Director4.7yrsno data3.15%
€ 250.9k
Ronnie Hershman
Independent Director4.8yrsno data8.05%
€ 642.0k
Sheila Copps
Member of Board of Advisors4.7yrsno datano data
Hari Kumar
Member of Scientific Advisory Board7yrsno datano data
York Hsiang
Member of Scientific Advisory Board4.8yrsno datano data
Johannes Grillari
Member of Scientific Advisory Board2.3yrsno datano data
Ernst von Schwarz
Member of Scientific Advisory Board2.3yrsno datano data

4.8yrs

Average Tenure

68yo

Average Age

Experienced Board: 2VF0's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 15:36
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hemostemix Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siddharth RajeevFundamental Research Corp.